ansunbiopharma.comHealthcare / BioTech & PharmaFounded: 2003Funding to Date: $165.2MM
Ansun Biopharma, founded in 2003, is a biopharmaceutical company seeking to develop innovative antiviral therapies. Ansun Biopharma's therapy is designed with the goal of utilizing a host-directed anti-viral biological product that aims to treat respiratory viral infections such as influenza virus, para influenza virus, and metapneumovirus. Ansun Biopharma is headquartered in San Diego, California.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/15/2018 | Series B | $100MM | $xx.xx | $466.82MM | Lilly Asia Ventures, Matrix Partners China, Yuanming Capital, Lyfe Capital, 3E Bioventures | |
Price per Share
$xx.xx
Shares Outstanding
67,290,223
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Lilly Asia Ventures, Matrix Partners China, Yuanming Capital, Lyfe Capital, 3E Bioventures
|
||||||
05/14/2018 | Series A-2 | $5.2MM | $xx.xx | $334.66MM | Sinopharm Healthcare Fund, Lilly Asia Ventures, Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, Joincap Investment | |
Price per Share
$xx.xx
Shares Outstanding
5,492,706
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Sinopharm Healthcare Fund, Lilly Asia Ventures, Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, Joincap Investment
|
||||||
05/14/2018 | Series A-1 | $60MM | $xx.xx | $334.66MM | Sinopharm Healthcare Fund, Lilly Asia Ventures, Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, Joincap Investment | |
Price per Share
$xx.xx
Shares Outstanding
47,543,582
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Sinopharm Healthcare Fund, Lilly Asia Ventures, Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, Joincap Investment
|